Interaction of blood components with cathelicidins and their modified versions

Biomaterials

Volumn 69, Issue , 2015, Pages 201-211

  Yu, Kai ^a   Lai, Benjamin F L ^a   Gani, Jurnorain ^d   Mikut, Ralf ^c   Hilpert, Kai ^d   Kizhakkedathu, Jayachandran N ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antimicrobial peptides; Biocompatibility; Blood coagulation; Blood interaction; Hemolytic activity; Infectious diseases; Novel antibiotics

Indexed keywords

ANTIBIOTICS; BIOCOMPATIBILITY; CHEMICAL ACTIVATION; COAGULATION; HYDROPHOBICITY; MICROORGANISMS; PEPTIDES; PLATELETS;

ANTIMICROBIAL PEPTIDE; BLOOD COAGULATION; BLOOD INTERACTIONS; HEMOLYTIC ACTIVITY; INFECTIOUS DISEASE; NOVEL ANTIBIOTICS;

DRUG INTERACTIONS;

BACTENECIN; CATHELICIDIN; INDOLICIDIN; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD COMPONENT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HEMOLYSIS; HUMAN; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; AMINO ACID SEQUENCE; BACTERIAL INFECTIONS; BACTERIUM; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE AGGREGATION; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL INFECTIONS; BLOOD COAGULATION; CATHELICIDINS; COMPLEMENT ACTIVATION; ERYTHROCYTE AGGREGATION; HEMOLYSIS; HUMANS; MOLECULAR SEQUENCE DATA; PLATELET ACTIVATION;

EID: 84940736010     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.08.003     Document Type: Article

References (50)

1. WHO Antimicrobial Resistance: Global Report on Surveillance 2014, http://www.who.int/drugresistance/documents/surveillancereport/en/.
2. Hancock R.E.W., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24:1551-1557.
3. Fjell C.D., Hiss J.A., Hancock R.E.W., Schneider G. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 2012, 11:37-51.
4. Nan Y.H., Bang J.K., Shin S.Y. Design of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent anti-inflammatory activity. Peptides 2009, 30:832-838.
5. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 2007, 13:975-980.
6. Han F.F., Liu Y.F., Xie Y.G., Gao Y.H., Luan C., Wang Y.Z. Antimicrobial peptides derived from different animals: comparative studies of antimicrobial properties, cytotoxicity and mechanism of action. World J. Microbiol. Biotechnol. 2011, 27:1847-1857.
7. Bechinger B., Salnikov E.S. The membrane interactions of antimicrobial peptides revealed by solid-state NMR spectroscopy. Chem. Phys. Lipids 2012, 165:282-301.
8. Melo M.N., Ferre R., Castanho M.A.R.B. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat. Rev. Microbiol. 2009, 7:245-250.
9. Nguyen L.T., Haney E.F., Vogel H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011, 29:464-472.
10. Haynie S.L., Crum G.A., Doele B.A. Antimicrobial activities of amphiphilic peptides covalently bonded to a water-insoluble resin. Antimicrob. Agents Chemother. 1995, 39:301-307.
11. Liu S.P., Zhou L., Lakshminarayanan R., Beuerman R.W. Multivalent antimicrobial peptides as therapeutics: design principles and structural diversities. Int. J. Pept. Res. Ther. 2010, 16:199-213.
12. Willcox M.D.P., Hume E.B.H., Aliwarga Y., Kumar N., Cole N. A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. J. Appl. Microbiol. 2008, 105:1817-1825.
13. Dathe M., Schumann M., Wieprecht T., Winkler A., Beyermann M., Krause E., et al. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996, 35:12612-12622.
14. Deslouches B., Phadke S.M., Lazarevic V., Cascio M., Islam K., Montelaro R.C., et al. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob. Agents Chemother. 2005, 49:316-322.
15. Tam J.P., Lu Y.A., Yang J.L. Antimicrobial dendrimeric peptides. Eur. J. Biochem. 2002, 269:923-932.
16. Saravanan R., Li X., Lim K.Y., Mohanram H., Peng L., Mishra B., et al. Design of short membrane selective antimicrobial peptides containing tryptophan and arginine residues for improved activity, salt-resistance, and biocompatibility. Biotechnol. Bioeng. 2014, 111:37-49.
17. Brandenburg L.O., Merres J., Albrecht L.J., Varoga D., Pufe T. Antimicrobial peptides: multifunctional drugs for different applications. Polymers 2012, 4:539-560.
18. Allison B.C., Applegate B.M., Youngblood J.P. Hemocompatibility of hydrophilic antimicrobial copolymers of alkylated 4-vinylpyridine. Biomacromolecules 2007, 8:2995-2999.
19. Wang B., Navath R.S., Menjoge A.R., Balakrishnan B., Bellair R., Dai H., et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int. J. Pharm. 2012, 395:298-308.
20. Jones C.F., Campbell R.A., Brooks A.E., Assemi S., Tadjiki S., Thiagarajan G., et al. Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano 2010, 6:9900-9910.
21. Ilker M.F., Nusslein K., Tew G.N., Coughlin E.B. Tuning the hemolytic and antibacterial activities of amphiphilic polynorbornene derivatives. J. Am. Chem. Soc. 2004, 126:15870-15875.
22. Ziemba B., Halets I., Shcharbin D., Appelhans D., Voit B., Pieszynski I., et al. Influence of fourth generation poly(propyleneimine) dendrimers on blood cells. J. Biomed. Mater. Res. Part A 2012, 100A:2870-2880.
23. Palermo E.F., Sovadinova I., Kuroda K. Structural determinants of antimicrobial activity and biocompatibility in membrane-disrupting methacrylamide random copolymers. Biomacromolecules 2009, 10:3098-3107.
24. Venkataraman S., Zhang Y., Liu L.H., Yang Y.Y. Design, syntheses and evaluation of hemocompatible pegylated-antimicrobial polymers with well-controlled molecular structures. Biomaterials 2010, 31:1751-1756.
25. Shenoi R.A., Kalathottukaren M.T., Travers R.J., Lai B.F.L., Creagh A.L., Lange D., et al. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci. Transl. Med. 2014, 6. 260ra150.
26. Kosciuczuk E.M., Lisowski P., Jarczak J., Strzalkowska N., Jozwik A., Horbanczuk J., et al. Cathelicidins: family of antimicrobial peptides. A review. Mol. Biol. Rep. 2012, 39:10957-10970.
27. Hamill P., Brown K., Jenssen H., Hancock R.E.W. Novel anti-infectives: is host defence the answer?. Curr. Opin. Biotechnol. 2008, 19:628-636.
28. Vandamme D., Landuyt B., Luyten W., Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 2012, 280:22-35.
29. Wu M.H., Hancock R.E.W. Improved derivatives of bactenecin, a cyclic dodecameric antimicrobial cationic peptide. Antimicrob. Agents Chemother. 1999, 43:1274-1276.
30. Hilpert K., Volkmer-Engert R., Walter T., Hancock R.E.W. High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 2005, 23:1008-1012.
31. Hilpert K., Elliott M.R., Volkmer-Engert R., Henklein P., Donini O., Zhou Q., et al. Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem. Biol. 2006, 13:1101-1107.
32. Wiegand I., Hilpert K., Hancock R.E.W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 2008, 3:163-175.
33. Mikut R., Hilpert K. Interpretable features for the activity prediction of short antimicrobial peptides using fuzzy logic. Int. J. Pept. Res. Ther. 2009, 15:129-137.
34. Mikut R. Computer-based analysis, visualization, and interpretation of antimicrobial peptide activities. Methods Mol. Biol. 2010, 618:287-299.
35. Subbalakshmi C., Krishnakumari V., Nagaraj R., Sitaram N. Requirements for antibacterial and hemolytic activities in the bovine neutrophil derived 13-residue peptide indolicidin. FEBS Lett. 1996, 395:48-52.
36. Johansson J., Gudmundsson G.H., Rottenberg M.E., Berndt K.D., Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 1998, 273:3718-3724.
37. Domanski D.M., Bryszewska M., Salamonczyk G. Preliminary evaluation of the behavior of fifth-generation thiophosphate dendrimer in biological systems. Biomacromolecules 2004, 5:2007-2012.
38. Wang P., Zhao X.H., Wang Z.Y., Meng M., Li X., Ning Q.A. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. Cancer Lett. 2010, 298:34-49.
39. Letcher R.L., Chien S., Pickering T.G., Sealey J.E., Laragh J.H. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am. J. Med. 1981, 70:1195-1202.
40. Bajaj S.P., Joist J.H. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin. Thromb. Hemost. 1999, 25:407-418.
41. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. 2003, 33:4-15.
42. Bolliger D., Seeberger M.D., Tanaka K.A. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transf. Med. Rev. 2012, 26:1-13.
43. Walport M.J. Advances in immunology: complement (first of two parts). N. Engl. J. Med. 2001, 344:1058-1066.
44. Meerasa A., Huang J.G., Gu F.X. CH50: a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction. Curr. Drug Deliv. 2011, 8:290-298.
45. Fauchere J.L., Pliska V. Hydrophobic parameters-pi of amino-acid side-chains from the partitioning of N-acetyl-amino acid amides. Eur. J. Med. Chem. 1983, 18:369-375.
46. Eisenberg D., Schwarz E., Komaromy M., Wall R. Analysis of membrane and surface protein sequence with the hydrophobic moment plot. J. Mol. Biol. 1984, 179:125-142.
47. Chou H.T., Kuo T.Y., Chiang J.C., Pei M.J., Yang W.T., Yu H.C., et al. Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp. Int. J. Antimicrob. Agents 2008, 32:130-138.
48. Ni Ainle F., Preston R.J.S., Jenkins P.V., Nel H.J., Johnson J.A., Smith O.P., et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009, 114:1658-1665.
49. Chu A.J., Beydoun S., Mathews S.T., Hoang J. Novel anticoagulant polyethylenimine: inhibition of thrombin-catalyzed fibrin formation. Arch. Biochem. Biophys. 2003, 415:101-108.
50. Scully M.F., Weerasinghe K., Kakkar V.V. Inhibition of contact activation by platelet factor-4. Thromb. Res. 1980, 20:461-466.